CVAC Systems to Present Data Showing Dramatic Enhancement of Metabolism of Cholesterol into Testosterone, and Improved Blood Lipid and Glucose Profiles in Diabetics

CVAC Systems will present its proprietary patent-pending process, validation data and, for the first time to a large audience in a non-confidential venue, human data demonstrating the scientific pathway for its potential in diabetes, insulin resistance and metabolic syndrome. This remarkable breakthrough data will be presented to attendees of Medtech Insight's IN3-West conference at 3:20 PM at the Hyatt Regency Hotel in Irvine California on February 27, 2007.

Temecula, CA (PRWEB) February 24, 2007 -- CVAC Systems, Inc., the developer of Cyclic Variations in Altitude Conditioning™ technology, will present remarkable breakthrough data to attendees of Medtech Insight's IN3-West conference at 3:20 PM at the Hyatt Regency Hotel in Irvine California on February 27, 2007.

Joining at least 40 other start-ups with a focus on medical device innovation, CVAC Systems will present its proprietary patent-pending process, validation data and, for the first time to a large audience in a non-confidential venue, human data demonstrating the scientific pathway for its potential in diabetes, insulin resistance and metabolic syndrome.

"Our new data on CVAC users are especially important because recent data from a study of 950 men in the Massachusetts Male Aging Study published in The Journal of Clinical Endocrinology & Metabolism in March 2006 links low total testosterone levels to the development of metabolic syndrome. Additionally, The Rancho Bernardo Study of 294 men published by the American Diabetes Association in Diabetes Care in 2002 links low total testosterone to the development of type 2 diabetes and insulin resistance. Also, the March 15, 2006 issue of the Journal of the American Medical Association contains a systematic review and meta-analysis from researchers from Harvard Medical School in which they concluded that high testosterone levels are associated with a lower risk of the development of type 2 diabetes in men," commented Allen Ruszkowski, President and CEO of CVAC Systems, Inc.

Ruszkowski commented further, "I am thrilled to be able to share the world's first data documenting improvements in lipid levels, blood glucose and steroidogenesis with the attendees of Medtech Insight's IN3 conference."

The CVAC process encompasses scientifically validated intermittent hypoxic (high-altitude) training (IHT) to trigger the human body's natural high-altitude adaptation response. The high-altitude adaptation response is scientifically understood to evoke increases in oxygenation of tissues. The CVAC process has the proven ability to enhance tissue oxygenation and the potential ability to remove toxins from the body. This suggests that it could benefit individuals who experience the limit of human performance, whether it is a result of athletic exertion, sickness, or the aging process. Moreover, CVAC Systems is focusing its efforts to study the potential value of the CVAC process in managing and treating diabetes, insulin resistance, and metabolic syndrome.

About CVAC Systems, Inc.
CVAC Systems, Inc., headquartered in Temecula, Calif., is privately funded and is seeking to place CVAC systems at key luminary research sites for the development of several patent-pending applications such as performance enhancement, disease prevention, therapy and advanced health. For these plans, the Company is seeking a first-round venture/institutional financing.

Please note: The information contained within this document is intended for prospective researchers only, and is not intended for patients or health care providers. Any references to therapeutic applications are for discussion and research purposes only.

###